CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1-3
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients4-6
If approved by the European Commission (EC), this would be upadacitinib's fifth therapeutic indication in the EU
The EC decision is anticipated in the third quarter of 2022
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.